Trending News: SGLT2 Inhibitors Reduce Cardiovascular Disease Risk in Patients with Type 2 Diabetes
Top news of the day from across the health care landscape.
A greater annual increase in arterial stiffness in patients with chronic obstructive pulmonary disease (COPD) may be associated with the severity of emphysema, systematic inflammation, and dyslipidemia, according to The American Journal of Managed Care. Researchers examined arterial stiffness in patients with COPD by performing annual assessments of lung function, blood gases, systematic inflammation, serum lipids, and blood pressure. An increase in annual augmentation index indicated progressive rigidity of the arterial wall in patients with COPD over time and increasing systematic inflammation and dyslipidemia enhanced the increasing evolution of arterial stiffness.
The SGLT2 inhibitor drug class has demonstrated a 12% reduction in major adverse cardiovascular events, a 17% reduction in cardiovascular death, and a 32% reduction in hospitalizations for heart failure in patients with type 2 diabetes, according to HCP Live. Using data from 4 studies, investigators sought to evaluate the cardiovascular benefits and effects on safety outcomes of SGLT2 inhibition on a population and individual basis in patients without and with established cardiovascular disease (CVD). Investigators suggest that SGLT2 inhibition protects against CVD and death in patients with type 2 diabetes.
A phase 1 clinical trial has begun enrolling healthy adult volunteers to test the safety and efficacy of monoclonal antibody CIS43LS (mAb CIS43LS) as prophylaxis against malaria, according to Contagion Live. The investigators plan to enroll up to 73 volunteers aged between 18 and 50 years who have never had malaria. After receiving the monoclonal antibody, the participants will be exposed to malaria-carrying mosquitos under controlled conditions. If the monoclonal antibody is effective through the goal of 3 to 6 months, it could be used to protect travelers without the need for a daily pill.